Search - tctmd.com

Displaying 1 - 20 of 23

Sort: Relevancy | Date

News Conference News ESC 2025

Mixed Results for Beta-blockers in Post-MI Patients With Preserved EF

Michael O'Riordan

August 30, 2025

News Conference News ESC 2024

‘Unlocking’ Scaffold Matches DES in Wide Range of PCI Patients, Including ACS

Michael O'Riordan

September 09, 2024

News Conference News ESC 2020

In Long-term, Real-world Data, CABG Bests PCI for Diabetic Patients With MVD

Yael L. Maxwell

September 01, 2020

News Conference News ESC 2019

BIOSTEMI: Ultrathin-Strut Orsiro Superior to Xience for 1-Year TLF After Primary PCI

Caitlin E. Cox

September 10, 2019

News Conference News ESC 2019

For A-fib/PCI Combo, Edoxaban Matches VKA but Not Superior: ENTRUST-AF PCI

Todd Neale

September 03, 2019

News Conference News ESC 2019

Ticagrelor Risky in Diabetic Patients With Stable CAD: THEMIS

Michael O'Riordan

September 01, 2019

News Conference News ESC 2018

Too Little, Too Late? Absorb BVS Shows Promising Results in STEMI Patients

Michael O'Riordan

August 28, 2018

News Conference News ESC 2017

BIOFLOW V: ‘Ultrathin-Strut’ Stent Beats Out Xience at 12 Months

Shelley Wood

August 30, 2017

News Conference News ESC 2017

ESC Updates Guidelines for Treating STEMI Patients

Michael O'Riordan

August 27, 2017

Presentation ESC 2016

Drug-Eluting vs Bare Metal Stents in Saphenous Vein Grafts: The Prospective Randomized BASKET-SAVAGE Trial

Presenter: Raban V. Jeger

August 31, 2016

News Conference News ESC 2016

BASKET-SAVAGE: DES Reign for Saphenous Vein Graft PCI Amid Declining Use

Shelley Wood

August 31, 2016

News Conference News ESC 2016

NORSTENT: Do Modern-day Bare-Metal Stents Stand Up to Drug-Eluting Stents?

Shelley Wood

August 30, 2016

News Conference News ESC 2015

EXAMINATION: STEMI Patients Fare Better at 5 Years With EES vs BMS

Caitlin E. Cox

September 02, 2015

News Conference News ESC 2014

PROTECT: ZES Sustain Lead Over SES at 5 Years

Caitlin E. Cox

September 03, 2014

News Conference News ESC 2014

BIOSCIENCE: Biodegradable Polymer SES Noninferior to Durable Polymer EES in All-Comers Trial

Yael L. Maxwell

September 01, 2014

Presentation ESC 2014

SCAAR: Lower late and very late stent thrombosis rates with new generation drug eluting stents compared to bare metal stents

Presenter: Christoph Varenhorst

August 30, 2014

News Conference News ESC 2014

SCAAR Confirms Low Very Late Stent Thrombosis Risk with Newer DES

Todd Neale

August 30, 2014

News Conference News ESC 2012

OCTOPUS Looks at Vessel Healing After DES vs. BMS Plus Paclitaxel Balloon

Caitlin E. Cox

August 29, 2012

News Conference News ESC 2012

Stent Thrombosis Surprise: Rates Low, Similar for Endeavor and Cypher at 3 Years

August 27, 2012

News Conference News

Two Trials Show Favorable Results with XIENCE V vs. Earlier DES, BMS

September 02, 2011

Advertisement

Mixed Results for Beta-blockers in Post-MI Patients With Preserved EF

‘Unlocking’ Scaffold Matches DES in Wide Range of PCI Patients, Including ACS

In Long-term, Real-world Data, CABG Bests PCI for Diabetic Patients With MVD

BIOSTEMI: Ultrathin-Strut Orsiro Superior to Xience for 1-Year TLF After Primary PCI

For A-fib/PCI Combo, Edoxaban Matches VKA but Not Superior: ENTRUST-AF PCI

Ticagrelor Risky in Diabetic Patients With Stable CAD: THEMIS

Too Little, Too Late? Absorb BVS Shows Promising Results in STEMI Patients

BIOFLOW V: ‘Ultrathin-Strut’ Stent Beats Out Xience at 12 Months

ESC Updates Guidelines for Treating STEMI Patients

Drug-Eluting vs Bare Metal Stents in Saphenous Vein Grafts: The Prospective Randomized BASKET-SAVAGE Trial

BASKET-SAVAGE: DES Reign for Saphenous Vein Graft PCI Amid Declining Use

NORSTENT: Do Modern-day Bare-Metal Stents Stand Up to Drug-Eluting Stents?

EXAMINATION: STEMI Patients Fare Better at 5 Years With EES vs BMS

PROTECT: ZES Sustain Lead Over SES at 5 Years

BIOSCIENCE: Biodegradable Polymer SES Noninferior to Durable Polymer EES in All-Comers Trial

SCAAR: Lower late and very late stent thrombosis rates with new generation drug eluting stents compared to bare metal stents

SCAAR Confirms Low Very Late Stent Thrombosis Risk with Newer DES

OCTOPUS Looks at Vessel Healing After DES vs. BMS Plus Paclitaxel Balloon

Stent Thrombosis Surprise: Rates Low, Similar for Endeavor and Cypher at 3 Years

Two Trials Show Favorable Results with XIENCE V vs. Earlier DES, BMS

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content